Anlon Healthcare issued a corrigendum to its Annual General Meeting (AGM) notice on August 25, 2026, addressing observations from the Bombay Stock Exchange and National Stock Exchange regarding its proposed preferential share issue.

The company plans to hold its 13th AGM on September 5, 2026, to seek shareholder approval for the issuance and allotment of equity shares on a preferential basis. The corrigendum revises specific clauses in the notice and explanatory statement to align with regulatory requirements raised by the exchanges on August 18 and August 19, 2026.

Issue Details and Pricing

The preferential issue involves two components: an acquisition of shares from Anlon Orthoplastics Private Limited (AOPL) and a buyback-linked preferential issue (BLPL). The total value of the AOPL component is ₹1,165,179,600, while the BLPL component totals ₹367,840,000.

Shares are being allotted at a price of ₹17.85 per equity share. This pricing is based on the volume-weighted average price on the NSE during the 90 trading days preceding the relevant date, which was determined to be ₹17.78. An independent registered valuer, CA Gaurang Agarwal, confirmed this fair value in a report dated August 6, 2026.

Allotment Structure

The AOPL component involves the allotment of 6,52,76,283 shares to 159 proposed allottees. The largest single allottee in this segment is Punitkumar Rameshbhai Rasadia, who is proposed to receive 1,75,23,043 shares valued at ₹312,786,300.

The BLPL component includes the allotment of 2,06,07,334 shares to 171 proposed allottees. Sanjukumar Rajeshbhai Savani is the largest recipient in this category, with 34,82,353 shares valued at ₹62,160,000.

Promoter Subscription

Only two promoters have indicated an intention to subscribe to the offer:

• Punitkumar Rameshbhai Rasadia (Promoter and Chairman & Managing Director): 1,84,19,402 shares
• Meet Atulkumar Vachhani (Promoter and Whole Time Director): 93,51,099 shares

Shareholding Pattern Impact

Post-issue, the promoter group's shareholding is expected to decrease from 52.68% to 49.85%. Conversely, public shareholding will rise from 47.32% to 50.15%, ensuring compliance with minimum public holding norms. The total number of equity shares will increase from 53,15,15,000 to 61,73,98,617.

Anlon Healthcare Limited has filed its annual report for the financial year ended March 31, 2026, reporting significant growth in both revenue and profitability. The company recorded a standalone revenue from operations of ₹1,764.99 crore, an increase from ₹1,202.87 crore in FY25. Standalone profit after tax (PAT) rose to ₹278.08 crore compared to ₹205.18 crore in the prior year.

The consolidated results show a revenue from operations of ₹1,719.66 crore and a consolidated PAT of ₹290.88 crore. The improvement in profitability was supported by operational efficiencies and strategic initiatives undertaken during the year.

Financial Performance

The company’s financials reflect strong top-line growth alongside improved bottom-line performance. Key figures for FY26 are outlined below:

Proposed Acquisitions

A key focus of the upcoming Annual General Meeting (AGM) is the proposed acquisition of two entities: Apiqo Organics Private Limited (AOPL) and Bizotic Lifescience Private Limited (BLPL). The company plans to acquire a 44.94% stake in AOPL and a 47.41% stake in BLPL through a share swap mechanism.

To facilitate this, Anlon Healthcare proposes a preferential allotment of up to 8,58,83,617 equity shares at a price of ₹17.85 per share. This transaction is structured as consideration other than cash, involving the issuance of swap shares to the existing shareholders of AOPL and BLPL.

• Apiqo Organics Acquisition: The company will issue approximately 6.53 crore shares to acquire the 44.94% stake in AOPL for a total consideration of ₹116.52 crore.
• Bizotic Lifescience Acquisition: Approximately 2.06 crore shares will be issued to acquire the 47.41% stake in BLPL for a total consideration of ₹36.78 crore.

Upon completion, both entities are expected to become wholly-owned subsidiaries of Anlon Healthcare, subject to regulatory approvals and the transfer of remaining shares from minority shareholders.

Capital Structure Changes

The company also seeks approval to enhance its authorized share capital from ₹110 crore to ₹130 crore. This involves the creation of additional 10 crore equity shares of ₹2 each. This move supports the company’s long-term growth strategy and provides flexibility for future capital requirements.

Corporate Governance and AGM

The 13th Annual General Meeting is scheduled for September 5, 2026. Other agenda items include the reappointment of Chairman and Managing Director Punitkumar Rasadia and the appointment of Kishan Vinodkumar Raja as an Independent Director.

The company successfully completed its Initial Public Offering (IPO) in August 2025, raising ₹121.03 crore. It also executed a 1:1 bonus issue and a 1:5 stock split during the year, reflecting confidence in its long-term value creation.

What the Numbers Show

The divergence between standalone and consolidated revenues—₹1,764.99 crore versus ₹1,719.66 crore respectively—highlights the impact of recent acquisitions on the group structure. While standalone operations drove the primary growth engine, the consolidated figures include subsidiaries acquired later in the fiscal year (AOPL in January 2026 and BLPL in March 2026), indicating that full-year integration benefits will likely be more visible in subsequent periods.